Dicerna Pharmaceuticals Inc. (DRNA) Shares Down 5.6%
Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) shares dropped 5.6% during mid-day trading on Tuesday . The stock traded as low as $3.01 and last traded at $3.03, with a volume of 93,349 shares. The stock had previously closed at $3.21.
DRNA has been the subject of several analyst reports. Stifel Nicolaus cut their price target on shares of Dicerna Pharmaceuticals from $16.00 to $13.00 and set a “buy” rating for the company in a report on Thursday, June 30th. Cowen and Company reissued a “buy” rating on shares of Dicerna Pharmaceuticals in a report on Sunday, June 26th. Zacks Investment Research raised shares of Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.75 price target for the company in a report on Thursday, May 12th. Leerink Swann restated a “buy” rating on shares of Dicerna Pharmaceuticals in a research report on Tuesday, May 10th. Finally, Jefferies Group restated a “buy” rating and set a $19.00 target price on shares of Dicerna Pharmaceuticals in a research report on Tuesday, May 10th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $11.95.
The company’s market cap is $66.12 million. The firm has a 50-day moving average of $3.26 and a 200 day moving average of $4.59.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.75) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.84) by $0.09. Equities research analysts anticipate that Dicerna Pharmaceuticals Inc. will post ($3.34) EPS for the current fiscal year.
Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.